Stock Financial Ratios, Dividends, Split History

AQMS / Aqua Metals, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price3.66
Volume912,800.00
Market Cap ($M)105.02
Enterprise Value ($M)82.23
Book Value / Share2.05
Price / Book1.93
NCAV ($M)10.21
NCAV / Share0.36
Price / NCAV10.29
Share Statistics
Common Shares Outstanding 28,694,210
Common Stock Shares Outstanding 27,554,076
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.45
Return on Assets (ROA)-0.37
Return on Equity (ROE)-0.47
Balance Sheet (mrq) ($M)
Assets74.44
Liabilities15.48
Quick Ratio6.38
Current Ratio6.70
Income Statement (mra) ($M)
Operating Income-24.86
Net Income-26.58
Cash Flow Statement (mra) ($M)
Cash From Operations-19.00
Cash from Investing-8.65
Cash from Financing-8.65
Identifiers and Descriptors
CUSIP03837J101
Central Index Key (CIK)1621832

Split History

Stock splits are used by Aqua Metals, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

Related News Stories

Aqua Metals' (AQMS) Management on Q1 2018 Results - Earnings Call Transcript

2018-05-10 seekingalpha
Greetings and welcome to the Aqua Metals First Quarter 2018 Corporate Update Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. (5-2)

BRIEF-Aqua Metals And Kanen Wealth Management Reach Agreement To Strengthen Co's Board

2018-05-02 reuters
* AQUA METALS AND KANEN WEALTH MANAGEMENT REACH AGREEMENT TO STRENGTHEN COMPANY’S BOARD AND MANAGEMENT TEAM (5-0)

BRIEF-Aqua Metals Inc ‍Announces Plans for CEO Succession

2018-03-28 reuters
* AQUA METALS INC - IMPLEMENTING PLAN TO TRANSITION STEPHEN CLARKE FROM CURRENT POSITION AS PRESIDENT, CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF BOARD Source text for Eikon: Further company coverage: (5-2)

Aqua Metals 2017 Q4 - Results - Earnings Call Slides

2018-03-16 seekingalpha
The following slide deck was published by Aqua Metals in conjunction with their 2017 Q4 earnings call. (5-1)

BRIEF-Aqua Metals Announces Proposed Public Offering Of Common Stock

2017-12-07 reuters
* AQUA METALS INC - TO USE NET PROCEEDS FROM OFFERING FOR EXPANSION OF PRODUCTION ACTIVITIES AT AQUAREFINING FACILITY IN NEVADA Source text for Eikon: Further company coverage: (5-2)

CUSIP: 03837J101